Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […]
Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. These data, plus health outcomes research, are being presented at the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting was delivered in two oral presentations, both of which were selected […]
Ascentage Pharma has released results from a phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB). The results were presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting […]
A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet in Sweden, have been published in the journal Gut. Chronic infections of the hepatitis B virus (HBV) and hepatitis […]
The National Institute of Allergy and Infectious Disease (NIAID) has awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes hepatitis C. Hepatitis C is an illness that affects an estimated 71 million people worldwide. Hepatitis C Virus (HCV) […]
Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […]
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, has announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 that took place June 22-26 in London, U.K. David Cory, […]
A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […]
Despite the recent EU approval of the first hepatitis D treatment, low public awareness remains an obstacle to tackling this aggressive infection. Earlier this month, the peptide drug Hepcludex became the first drug greenlit for hepatitis D treatment in Europe. This was a conditional market authorization granted to the German company MYR Pharmaceuticals based on […]
Phase II results from Dutch biotech CyTuVax show its enhanced hepatitis B vaccine reduces non-responders by 13%. Around 15% of people receiving vaccines for hepatitis B fail to produce antibodies that protect them against the infection. These non-responders are often given more injections of the vaccine in an attempt to trigger the immune system, but […]
Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop an HIV vaccine using the Austrian company’s arenavirus-based technology. Hookipa’s lead candidate is a prophylactic vaccine for cytomegalovirus, a common infection that can be dangerous in people with weak immune systems, such as those with […]